Management of borderline resectable pancreatic cancer
- PMID: 20159519
- DOI: 10.1016/j.soc.2009.11.006
Management of borderline resectable pancreatic cancer
Abstract
Borderline resectable pancreatic cancer is an emerging stage of disease defined by computed tomogrpahy criteria, patient (Katz type B), or disease characteristics (Katz type C). These patients are particularly well suited to a surgery-last strategy with induction therapy consisting of chemotherapy (gemcitabine alone or in combination) followed by chemoradiation. With appropriate selection and preoperative planning, many patients with borderline resectable disease derive clinical benefit from multimodality therapy. The use of a standardized system for the staging of localized pancreatic cancer avoids indecision and allows for the optimal treatment of all patients guided by the extent of their disease. In this article, 2 case reports are presented, and the term borderline resectable pancreatic cancer is discussed. The advantages of neoadjuvant therapy and surgery are also discussed.
Similar articles
-
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.Am J Clin Oncol. 2016 Feb;39(1):1-7. doi: 10.1097/COC.0000000000000003. Am J Clin Oncol. 2016. PMID: 26132367
-
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?Ann Surg Oncol. 2014 Feb;21(2):662-9. doi: 10.1245/s10434-013-3396-5. Epub 2013 Nov 26. Ann Surg Oncol. 2014. PMID: 24276638
-
Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases.World J Surg Oncol. 2013 Feb 5;11:37. doi: 10.1186/1477-7819-11-37. World J Surg Oncol. 2013. PMID: 23379413 Free PMC article.
-
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.Surg Oncol Clin N Am. 2004 Oct;13(4):711-35, x. doi: 10.1016/j.soc.2004.06.005. Surg Oncol Clin N Am. 2004. PMID: 15350944 Review.
-
Management of a patient with borderline resectable pancreatic cancer. Case report and review.Oncology (Williston Park). 2008 Nov 30;22(13):1524-9. Oncology (Williston Park). 2008. PMID: 19133606 Review.
Cited by
-
Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience.Medicine (Baltimore). 2018 Dec;97(50):e13592. doi: 10.1097/MD.0000000000013592. Medicine (Baltimore). 2018. PMID: 30558029 Free PMC article.
-
Elastography Can Map the Local Inverse Relationship between Shear Modulus and Drug Delivery within the Pancreatic Ductal Adenocarcinoma Microenvironment.Clin Cancer Res. 2019 Apr 1;25(7):2136-2143. doi: 10.1158/1078-0432.CCR-18-2684. Epub 2018 Oct 23. Clin Cancer Res. 2019. PMID: 30352906 Free PMC article.
-
Borderline resectable pancreatic cancer: definitions and management.World J Gastroenterol. 2014 Aug 21;20(31):10740-51. doi: 10.3748/wjg.v20.i31.10740. World J Gastroenterol. 2014. PMID: 25152577 Free PMC article. Review.
-
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.J Surg Oncol. 2013 Sep;108(4):236-41. doi: 10.1002/jso.23392. J Surg Oncol. 2013. PMID: 23955427 Free PMC article.
-
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Int J Mol Sci. 2017 Jun 22;18(7):1338. doi: 10.3390/ijms18071338. Int J Mol Sci. 2017. PMID: 28640192 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
